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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the efficacy of administration of vitaminD and its hydroxylatedmetabolites in reducing asthma exacerbations and improving
asthma symptom control.
B A C K G R O U N D
Description of the condition
Asthma is a chronic inflammatory conditionof the airways, charac-
terised by recurrent attacks of breathlessness, wheezing, cough and
chest tightness, termed ’exacerbations’. The prevalence of asthma
varies widely between countries. In children, the prevalence of se-
vere asthma symptoms ranges from 0% (India) to 20.3% (Costa
Rica) (Lai 2009); in adults, the prevalence of doctor-diagnosed
asthma ranges from0.2% (China) to 21.0% (Australia) (To 2012).
Exacerbations represent the major cause of morbidity and mor-
tality in patients with asthma (Johnston 2006). Asthma exacerba-
tions are classified as severe when they result in hospitalisation or
death, and moderate when they prompt a need for a change in
treatment, such as initiation of systemic corticosteroids, without
causing death or hospitalisation (Reddel 2009). Common precip-
itants of asthma exacerbation include acute respiratory infections
and exposure to allergens and particulates (Singh 2006).
Description of the intervention
Vitamin D is a pre-pro-hormone that has two parent forms: chole-
calciferol (vitamin D3) and ergocalciferol (vitamin D2). Cholecal-
ciferol is synthesised in human skin from its precursor molecule 7-
dehydrocholesterol on exposure to ultraviolet B (UVB) radiation
in sunlight; it may also be ingested, either in the diet (primarily
from eating oily fish) or in vitamin D supplements. Ergocalciferol
is the plant and fungal form of the vitamin, which may occasion-
ally be ingested in the diet (primarily by eating fungi) or in vitamin
D supplements. In situations where cutaneous exposure to UVB
radiation of appropriate intensity is limited (e.g. during winter at
latitudes above 34ºN or below 34ºS, or in settings where people
do not regularly expose their skin to sunlight), dietary sources of
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vitaminD and/or vitaminD supplementsmay be required tomeet
the body’s vitamin D requirement (Holick 2007).
Following cutaneous synthesis or ingestion, both forms of parent
vitamin D undergo metabolism to form 25-hydroxyvitamin D
(25(OH)D), the major circulating vitamin D metabolite whose
serum concentration indicates vitamin D status. 25-hydroxyla-
tion may occur in the liver and in extra-hepatic tissues, includ-
ing leucocytes (Holick 2007). Serum 25(OH)D concentrations <
50 nmol/L are widely accepted to indicate vitamin D deficiency;
concentrations < 25 nmol/L represent profound deficiency. Con-
centrations of 50-74 nmol/L may represent a milder state of in-
adequate vitamin D status, commonly termed ‘vitamin D insuffi-
ciency’. 25(OH)D undergoes a second hydroxylation step at the
1-alpha position to form the active vitamin D metabolite 1,25-
dihydroxyvitamin D (1,25(OH)2D) - the steroid hormone and
active vitamin Dmetabolite which mediates the biological actions
of vitamin D by binding the vitamin D receptor to regulate gene
expression (Holick 2007). This 1-alpha hydroxylation step is catal-
ysed by the enzyme CYP27B1, which is expressed in multiple tis-
sues including the kidney, leucocytes and pulmonary epithelium;
expression of CYP27B1 in leucocytes and pulmonary epithelium
is up-regulated in response to infection and inflammation.
This review will include studies which evaluate the effects of ad-
ministration, by any route and at any dose, of vitamin D3, vi-
tamin D2, 25(OH)D or 1,25(OH)2D. Vitamin D3, vitamin D2
and 25(OH)D are usually administered orally; the ‘parent com-
pounds’ vitamin D3 and vitamin D2 may also be given intramus-
cularly. Intramuscular administration of a bolus dose of vitamin
D induces a slower increase and a lower peak in serum 25(OH)D
than oral administration of the same dose (Romagnoli 2008), and
consequently this route of administration is not widely employed
in clinical trials of vitamin D supplementation. The functional
in vivo half-life of 25(OH)D in the circulation is 1 to 2 months;
accordingly, it takes at least 3 months to attain steady-state con-
centrations of 25(OH)D in response to daily administration of vi-
tamin D (Heaney 2003). Because of the relatively long half-life of
25(OH)D, parent vitamin D and 25(OH)Dmay be administered
intermittently as well as daily: weekly and monthly dosing regi-
mens are often employed, andmorewidely spaceddosing regimens
are also used. However, dosing less frequently than two monthly
results in large non-physiological fluctuations in serum 25(OH)D
concentration, which may cause undesirable effects (Vieth 2009;
Martineau 2012; Hollis 2013). The influence of dosing interval
on biological responses to administration of vitamin D is an area
of active research in the field.
How the intervention might work
About 1 billion people worldwide are estimated to have 25(OH)D
levels < 75 nmol/L (Holick 2007). Inadequate vitamin D status
has been reported to be common among asthma patients in a vari-
ety of settings, and several studies have demonstrated independent
associations between inadequate vitamin D status and increased
risk of exacerbations (Brehm 2010; Brehm 2012; Confino-Cohen
2014). Administration of vitamin D3, vitamin D2 or 25(OH)D
results in increasing circulating concentrations of 25(OH)D. This
25(OH)D acts as a substrate for CYP27B1 expressed in the kid-
ney and multiple extra-renal tissues. Of particular relevance for
asthma, CYP27B1 expression in the airway and leucocytes is in-
duced during infection and inflammation, so that the active vita-
min D metabolite 1,25(OH)2D is synthesised locally in the lung.
1,25(OH)2D ligates the vitamin D receptor (VDR) to induce
antimicrobial activity (e.g. by induction of antimicrobial peptide
expression) and exert anti-inflammatory activity (e.g. by induc-
tion of the anti-inflammatory cytokine IL-10, suppression of pro-
inflammatory TNF and IFN-γ - inducible chemokines and inhi-
bition of LPS-induced synthesis of reactive oxygen species) (Lan
2014; Mann 2014). This combination of antimicrobial, antiviral
and anti-inflammatory activity might decrease the risk of exacer-
bations, which are often precipitated by respiratory infection, and
which are characterised by dysregulated pulmonary inflammation.
Of particular relevance to asthma, 1,25(OH)2D has been shown
to enhance responsiveness to inhaled corticosteroids (ICS) for pro-
duction of interleukin-10 (Xystrakis 2006). This finding raises the
possibility that administration of vitamin D or 25(OH)D may
therefore have a role in reducing exacerbation risk and improv-
ing symptom control in combination with ICS, as well as inde-
pendently. There is controversy, however, regarding what serum
25(OH)D concentration, if any, is optimum for reducing the risk
of asthma exacerbation.
Why it is important to do this review
There is considerable interest in the potential of administration
of vitamin D to reduce exacerbation risk and improve asthma
symptom control. Two small trials of vitamin D supplementation
in children with asthma treated with inhaled corticosteroids have
reported reduced rates of exacerbation among participants ran-
domised to the intervention arm (Majak 2011; Yadav 2014), and
one small trial showed no effect of vitamin D supplementation on
inflammatory markers or lung function (Bar Yoseph 2014). One
larger trial in adults has also reported a trend towards reduced
exacerbation rate in the intervention arm (adjusted Hazard Ratio
0.63, 95% confidence interval (CI) 0.39 to 1.01) (Castro 2014).
Other trials are either in progress or completed but as yet unpub-
lished. Meta-analysis of these trials has the potential to increase
statistical power to detect effects of administering vitamin D on
exacerbation risk and symptom control both in study populations
as a whole, and within subgroups who might be expected to derive
particular benefit from this intervention (e.g. those with lower vi-
tamin D status at enrolment).
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O B J E C T I V E S
To evaluate the efficacy of administration of vitamin D and its
hydroxylated metabolites in reducing asthma exacerbations and
improving asthma symptom control.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will review double-blind randomised placebo-controlled trials
of at least twelve weeks’ duration. We will include studies reported
as full-text and unpublished data. Studies published as abstract
only will also be included, but we will note that they are pending
definitive evaluation as and when fuller reports are available.
Types of participants
We will include children and adults with a clinical diagnosis of
asthma, based on the presence of characteristic symptoms and vari-
able airflow obstruction. No restrictions regarding disease severity,
baseline vitamin D status or duration of treatment with asthma
medication will be imposed, in order to maximise generalisability.
Types of interventions
We will include studies in which vitamin D3, vitamin D2,
25(OH)D or 1,25(OH)2D are administered at any dose.
Types of outcome measures
Primary outcomes
The primary outcome of this review is asthma exacerbation treated
with systemic corticosteroids.
Secondary outcomes
Effectiveness
1. Asthma exacerbation requiring hospital admission;
2. Asthma exacerbation precipitating an emergency
department visit;
3. Fatal asthma exacerbations;
4. Symptom control as judged by use of a validated
instrument;
5. Time off school or work;
6. Beta2agonist use;
7. Asthma quality of life as judged by use of a validated
instrument.
Physiological/biochemical
1. Peak expiratory flow monitoring;
2. Spirometric values (forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC));
3. Biomarkers of asthma control (exhaled nitric oxide, lower
airway eosinophilia in induced sputum or bronchoalveolar
lavage, other immunological parameters);
4. Airway reactivity.
Health economic
1. Costs from the perspective of healthcare providers.
Safety
1. Proportion of patients experiencing an adverse event
attributed to administration of vitamin D or its metabolites;
2. Proportion of patients experiencing any severe adverse
event, irrespective of causation;
3. Proportion of patients withdrawing from the trial.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group’s Spe-
cialisedRegister (CAGR), which ismaintained by the Trials Search
Co-ordinator for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct searches of
ClinicalTrials.gov (www.ClinicalTrials.gov), the WHO trials por-
tal (www.who.int/ictrp/en/), the ISRCTN clinical trials register
(http://www.controlled-trials.com/isrctn/ ), the Australian New
Zealand Clinical Trials Registry (http://www.anzctr.org.au/ ) and
the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/).
We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
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Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
We will contact a panel of international experts for additional
references and information on trials in progress.
Data collection and analysis
Selection of studies
Two review authors (ARM, AT) will independently screen for in-
clusion the titles and abstracts of all the potentially relevant studies
we identify as a result of the search, and code them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’.We will
retrieve the full-text study reports/publication and two review au-
thors (ARM, AT) will independently screen the full-text and iden-
tify studies for inclusion, and identify and record reasons for ex-
clusion of the ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third person
(CJG or AS). We will identify and exclude duplicates and collate
multiple reports of the same study so that each study rather than
each report is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table (Moher
2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. Two review authors (ARM, AT) will extract study charac-
teristics from included studies. We will extract the following study
characteristics.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, body mass
index, severity of condition, diagnostic criteria, baseline lung
function, smoking history, inclusion criteria, and exclusion
criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (ARM, AT) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third person (CJG or AS). One review author (AT)
will transfer data into the RevMan 2014 file.We will double-check
that data are entered correctly by comparing the data presented
in the systematic review with the study reports. A second review
author (ARM) will spot-check study characteristics for accuracy
against the trial reports.
Assessment of risk of bias in included studies
Two review authors (TBA, AT) will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (CJG or AS).We will assess the risk of bias accord-
ing to the following domains.
1. Random sequence generation;
2. Allocation concealment;
3. Blinding of participants and personnel;
4. Blinding of outcome assessment;
5. Incomplete outcome data;
6. Selective outcome reporting;
7. Other biases, including study size
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifica-
tion for our judgment in the ’Risk of bias’ table.Wewill summarise
the ’Risk of bias’ judgements across different studies for each of
the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient-reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios, since the rate of
exacerbations may vary widely between studies, and the weights
for each study using relative risk will be heavily dependent on the
choice of outcome measure. We will analyse continuous data as
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mean difference or standardised mean difference. We will enter
data presented as a scale with a consistent direction of effect.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
For outcomes measured at different time points, we will include
the longest time point after randomisation.
Unit of analysis issues
Where data are expressed in unconventional units of analysis we
will convert them to conventional units, liaising with authors if
required.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by a sensitivity
analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity (I2 >
40%) we will report it and explore possible causes by pre-specified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible small study biases.
Data synthesis
We expect significant heterogeneity: accordingly, we will use a
random-effects model and perform a sensitivity analysis with a
fixed-effect model.
An intention-to-treat model will be used to analyse data when
possible. Continuous data will be analysed as a mean difference;
dichotomous data will be reported as odds ratios. Number needed
to treat for an additional beneficial outcome (NNTB) and number
needed to treat for an additional harmful outcome (NNTH) for
adverse events will be calculated where appropriate, to give an
indication for each dichotomous outcome, to reflect the number
of patients required to achieve a benefit or disbenefit with the
intervention.
Means and standard deviations (SDs) will be used when available.
We will approach authors where data are not reported. Values will
be extracted from graphs if authors do not respond.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing outcomes: incidence of moderate/severe asthma exacerbation;
proportion of patients with one or more emergency department
attendance or hospitalisation for asthma; asthma symptom con-
trol; asthma quality of life; lung function; biomarkers of asthma
control; and incidence of severe adverse events attributed to ad-
ministration of vitamin D. We will use the five GRADE consid-
erations (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of a body of
evidence as it relates to the studies which contribute data to the
meta-analyses for the pre-specified outcomes.Wewill use methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) using GRADEpro software.
We will calculate NNTB from the control group event rate (unless
the population event rate is known) and odds ratios using the
Visual Rx NNT calculator (http://www.nntonline.net/visualrx/).
We will list trials in progress.
We will justify all decisions to down- or up-grade the quality of
studies using footnotes and we will make comments to aid readers’
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Baseline vitamin D status (e.g. serum 25(OH)D < 50
nmol/L vs. ≥ 50 nmol/L). If data on baseline vitamin D status
are unavailable, we will investigate whether the effects of
administering vitamin D vary according to proxy measures of
vitamin D status (e.g. season of randomisation, latitude of
residence);
2. Age (e.g. children aged < 5 years versus 5 to 16 years versus
adults);
3. Severity of asthma and concomitant asthma treatment
being taken (e.g. taking versus not taking ICS, taking versus not
taking leukotriene receptor antagonists);
4. The dose (e.g. daily equivalent of < 400 IU versus 400 to
2000 IU versus > 2000 IU) and form of vitamin D administered
(e.g. cholecalciferol versus calcitriol);
5. The frequency of administration (e.g. daily versus
intermittent bolus doses);
6. Genetic variation in pathways of vitamin D metabolism,
transport and signalling (e.g. GC 2/2 versus 2/1 versus 1/1
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genotype for the Gc polymorphism of the vitamin D binding
protein);
7. Body mass index (e.g. < 25 kg/m2versus ≥ 25 kg/m2).
We will use the following outcome in subgroup analyses.
1. Severe asthma exacerbation.
We will use the formal test for subgroup interactions in RevMan
2014 .
Sensitivity analysis
We plan to carry out the following sensitivity analysis:
1. Exclusion of publications at high risk of bias in one or more
of the following domains: sequence generation, allocation
concealment, blinding, completeness of outcome data or
selective outcome reporting.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (T he Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
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(Continued)
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
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16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to retrieve trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Vitamin D Explode All
#6 MeSH DESCRIPTOR Vitamin D Deficiency Explode All
#7 “vitamin d”
#8 #5 or #6 or #7
#9 #4 and #8
(in search line #1, MISC1 refers to the field in the record where the reference has been coded for condition, in this case, asthma)
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